NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Stock Forecast, Price & News

$1.28

0.00 (0.00%)

(As of 06/7/2023 ET)

Compare

Today's Range: $1.23
▼
$1.34
50-Day Range: $1.08
▼
$2.76
52-Week Range: $0.93
▼
$10.75

Volume: 13,346 shs
Average Volume: 49,595 shs
Market Capitalization: $30.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Impel Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 1,560.2% Upside
$21.25 Price Target
Short Interest: Healthy
4.21% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.40) to ($1.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

533rd out of 981 stocks

Pharmaceutical Preparations Industry

242nd out of 460 stocks

3.3

Analyst's Opinion

Consensus Rating
Impel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.25, Impel Pharmaceuticals has a forecasted upside of 1,560.2% from its current price of $1.28.
Amount of Analyst Coverage
Impel Pharmaceuticals has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.21% of the float of Impel Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Impel Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Impel Pharmaceuticals has recently decreased by 23.19%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Impel Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Impel Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMPL.

1.1

News and Social Media Coverage

Search Interest
3 people have searched for IMPL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
2 people have added Impel Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Impel Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.30% of the stock of Impel Pharmaceuticals is held by insiders.
Percentage Held by Institutions
63.92% of the stock of Impel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Impel Pharmaceuticals are expected to grow in the coming year, from ($3.40) to ($1.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Impel Pharmaceuticals is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Impel Pharmaceuticals is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Impel Pharmaceuticals (NASDAQ:IMPL) Stock

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IMPL Stock News Headlines

May 17, 2023 | uk.finance.yahoo.com

Impel Pharmaceuticals Inc. (IMPL)

May 13, 2023 | finance.yahoo.com

Impel Pharmaceuticals First Quarter 2023 Earnings: Misses Expectations

June 8, 2023 | Altimetry (Ad)

Biden's latest bailout--terrible for America?

And a consultant for the Dept. of Defense (Joel Litman) says this is all leading to an event in the next 20 months that could help some get vastly wealthier… but also make it harder than ever to hang onto any money you make.This might be the most important development affecting you and your money over the next few years—

May 12, 2023 | msn.com

Recap: Impel Pharmaceuticals Q1 Earnings

May 12, 2023 | finance.yahoo.com

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023 | msn.com

Earnings Outlook For Impel Pharmaceuticals

May 11, 2023 | americanbankingnews.com

Impel Pharmaceuticals (IMPL) Set to Announce Quarterly Earnings on Friday

May 10, 2023 | msn.com

Impel Pharmaceuticals gets new CFO

June 8, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 10, 2023 | finance.yahoo.com

Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer

May 5, 2023 | finance.yahoo.com

Investors in Impel Pharmaceuticals (NASDAQ:IMPL) from a year ago are still down 67%, even after 26% gain this past week

May 5, 2023 | finance.yahoo.com

Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

April 26, 2023 | finance.yahoo.com

Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications

April 11, 2023 | finance.yahoo.com

Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting

April 3, 2023 | americanbankingnews.com

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Short Interest Update

March 30, 2023 | finance.yahoo.com

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Full-Year Results: Here's What Analysts Are Forecasting For This Year

March 27, 2023 | finance.yahoo.com

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Q4 2022 Earnings Call Transcript

March 26, 2023 | finance.yahoo.com

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Analysts Just Slashed This Year's Revenue Estimates By 12%

March 24, 2023 | msn.com

Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates

March 24, 2023 | finance.yahoo.com

Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 17, 2023 | finance.yahoo.com

Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023

March 3, 2023 | finance.yahoo.com

Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March

February 24, 2023 | seekingalpha.com

Impel Pharma says reducing headcount by 16%, eliminating pipeline programs

February 23, 2023 | msn.com

Why Domino's Pizza Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

February 22, 2023 | finance.yahoo.com

Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity

February 22, 2023 | finance.yahoo.com

Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity

February 14, 2023 | nasdaq.com

Ocular Therapeutix (OCUL) Moves 35.1% Higher: Will This Strength Last?

See More Headlines

IMPL Price History

30 days | 90 days | 365 days | Advanced Chart

IMPL Company Calendar

Last Earnings: 3/24/2023
Today: 6/07/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IMPL
CUSIP: N/A
CIK: 1445499
Web: www.Impelnp.com
Phone: 206-568-1466
Fax: N/A
Employees: 129
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.25
High Stock Price Forecast: $40.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +1,071.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-106,310,000.00
Net Margins: -716.73%
Pretax Margin: -716.73%
Return on Equity: -701.26%
Return on Assets: -115.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.33
Quick Ratio: 1.97

Sales & Book Value

Annual Sales: $12.65 million
Price / Sales: 2.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.86) per share
Price / Book: -0.69

Miscellaneous

Outstanding Shares: 23,750,000
Free Float: 22,253,000
Market Cap: $30.40 million
Optionable: Not Optionable
Beta: -0.27

Key Executives

Mr. Adrian Adams (Age 71)
Chairman & CEO
Comp: $956.42k

Dr. John D. Hoekman Ph.D. (Age 41)
Co-Founder and Chief Technology & Devel. Officer

Dr. John H. Leaman M.D. (Age 49)
Chief Financial & Bus. Officer
Comp: $964.37k

Mr. Leonard S. Paolillo (Age 43)
Chief Commercial Officer
Comp: $496.7k

Ms. Jennifer L. Berman
VP of Marketing

Ms. Patty Billingsley
VP of Sales

Ms. Sarah Wille
VP of HR

Dr. Stephen Bevan Shrewsbury M.B. Ch.B. (Age 65)
M.D., Chief Medical Officer

Dr. Lynn C. Gold Ph.D. (Age 65)
Sr. VP of Regulatory

Mr. Scott Youmans (Age 55)
Sr. VP of Technical Operations

Key Competitors

View All Competitors

Institutional Ownership

State Street Corp
Sold 12,300 shares on 5/16/2023
Ownership: 0.106%

View All Institutional Transactions

IMPL Stock - Frequently Asked Questions

Should I buy or sell Impel Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Impel Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMPL shares.
View IMPL analyst ratings or view top-rated stocks.
What is Impel Pharmaceuticals' stock price forecast for 2023?: 2 equities research analysts have issued 1 year price objectives for Impel Pharmaceuticals' stock. Their IMPL share price forecasts range from $5.00 to $40.00. On average, they predict the company's share price to reach $21.25 in the next twelve months. This suggests a possible upside of 1,560.2% from the stock's current price.
View analysts price targets for IMPL or view top-rated stocks among Wall Street analysts.
How have IMPL shares performed in 2023?: Impel Pharmaceuticals' stock was trading at $3.75 at the beginning of 2023. Since then, IMPL shares have decreased by 65.9% and is now trading at $1.28.
View the best growth stocks for 2023 here.
Are investors shorting Impel Pharmaceuticals?: Impel Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 326,000 shares, a drop of 23.2% from the April 30th total of 424,400 shares. Based on an average daily volume of 64,100 shares, the short-interest ratio is presently 5.1 days. Currently, 4.2% of the shares of the stock are short sold.
View Impel Pharmaceuticals' Short Interest.
When is Impel Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our IMPL earnings forecast.
How were Impel Pharmaceuticals' earnings last quarter?: Impel Pharmaceuticals Inc. (NASDAQ:IMPL) released its quarterly earnings results on Friday, March, 24th. The company reported ($0.97) EPS for the quarter, beating analysts' consensus estimates of ($1.04) by $0.07. The business had revenue of $5.01 million for the quarter, compared to analyst estimates of $4.06 million. Impel Pharmaceuticals had a negative trailing twelve-month return on equity of 701.26% and a negative net margin of 716.73%.

When did Impel Pharmaceuticals IPO?: (IMPL) raised $80 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow acted as the underwriters for the IPO.
What is Impel Pharmaceuticals' stock symbol?: Impel Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMPL."
Who are Impel Pharmaceuticals' major shareholders?: Impel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (0.11%). Insiders that own company stock include Adrian Adams, Global Strategic Fund I Venbio, Timothy S Nelson and Vivo Capital Viii, Llc.
View institutional ownership trends.
How do I buy shares of Impel Pharmaceuticals?: Shares of IMPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Impel Pharmaceuticals' stock price today?: One share of IMPL stock can currently be purchased for approximately $1.28.
How much money does Impel Pharmaceuticals make?: Impel Pharmaceuticals (NASDAQ:IMPL) has a market capitalization of $30.40 million and generates $12.65 million in revenue each year. The company earns $-106,310,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis.
How many employees does Impel Pharmaceuticals have?: The company employs 129 workers across the globe.
How can I contact Impel Pharmaceuticals?: The official website for the company is www.Impelnp.com. The company can be reached via phone at 206-568-1466.

This page (NASDAQ:IMPL) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial